SSGJ-706 alone and combined with chemotherapy or PD-1 inhibitors for advanced non-small cell lung cancer
Official title: A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Run by Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07171606 · Data updated 2026-11-12
This trial tests whether SSGJ-706 by itself or with chemotherapy and a PD-1 inhibitor can help adults with first-line advanced non-small cell lung cancer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. Industry-sponsored |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | October 24, 2025 |
| Main results expected | August 31, 2026 |
| Study ends | August 31, 2027 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT07171606 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically or cytologically confirmed first-line advanced or metastatic NSCLC, ECOG performance status 0–1, expected survival ≥3 months, adequate organ function, and no uncontrolled CNS metastases or known allergy to SSGJ-706.
✕Probably not a fit
Patients with uncontrolled or symptomatic brain metastases, significant organ or marrow dysfunction, recent high‑grade toxicity from prior anticancer therapy, pregnancy or breastfeeding, or known hypersensitivity to SSGJ-706 are unlikely to qualify or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase II trial enrolls adults with first-line advanced or metastatic NSCLC and has two parts: part 1 explores SSGJ-706 monotherapy across several preset dose levels, and part 2 tests SSGJ-706 combined with standard chemotherapy regimens and a PD-1 inhibitor. Each part measures tumor response and safety to identify active dose(s) and tolerability. Eligible participants must have ECOG 0–1, adequate organ and bone marrow function, and no uncontrolled symptomatic central nervous system metastases. The sponsor is Shenyang Sunshine Pharmaceutical and the trial is conducted at Shanghai Pulmonary Hospital.
Why it matters
Potential benefit: If effective, SSGJ-706 could shrink tumors, delay disease progression, or improve responses when given alone or with standard chemotherapy and immunotherapy.
How similar studies have gone: Other trials combining targeted agents with chemotherapy or PD-1 inhibitors have benefited selected NSCLC groups, but SSGJ-706 appears to be a novel agent without large published efficacy data yet.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Males and/or females over age 18 2. Histologically and/or cytologically documented local advanced or metastatic NSCLC . 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Expected survival \>=3 months. 5. Signed informed consent form. Exclusion Criteria: 1. Known uncontrolled or symptomatic central nervous system metastatic disease. 2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0). 3. Inadequate organ or bone marrow function. 4. Pregnant or breast-feeding woman. 5. Known allergies, hypersensitivity, or intolerance to SSGJ-706 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Where it's running
-
Institute of The Shanghai Pulmonary Hospital
Shanghai, China Recruiting
Study contacts
- Study coordinator: Shengxiang Ren
- Email: harry_ren@126.com
- Phone: 13816756732
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HRS-4642 plus AG vs AG alone in first-line advanced pancreatic cancer with KRAS G12D mutation
This trial tests whether adding HRS-4642 to AG therapy helps people with KRAS G12D‑mutant advanced or metastatic pancreatic cancer in their first-line treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.